National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease

被引：168

作者：

Myers, Gary L. ^{[1
]}

Christenson, Robert H. M. ^{[2
]}

Cushman, Mary ^{[3
]}

Ballantyne, Christie M. ^{[4
]}

Cooper, Gerald R. ^{[1
]}

Pfeiffer, Christine M. ^{[1
]}

Grundy, Scott M. ^{[5
]}

Labarthe, Darwin R. ^{[1
]}

Levy, Daniel ^{[6
]}

Rifai, Nader ^{[7
,8
]}

Wilson, Peter W. F. ^{[9
]}

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA

[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[3] Univ Vermont, Colchester, VT USA

[4] Baylor Coll Med, Houston, TX 77030 USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[6] Framingham Heart Dis Epidemiol Study, Framingham, MA USA

[7] Harvard Univ, Sch Med, Boston, MA USA

[8] Childrens Hosp, Boston, MA 02115 USA

[9] Emory Univ, Sch Med, Atlanta, GA USA

来源：

CLINICAL CHEMISTRY | 2009年 / 55卷 / 02期

关键词：

D O I：

10.1373/clinchem.2008.115899

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

100118 [医学信息学]; 100208 [临床检验诊断学];

摘要：

BACKGROUND: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging biomarkers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use. CONTENT: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected lipoprotein subclasses and particle concentration, lipoprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines. CONCLUSIONS: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention. (C) 2008 American Association for Clinical Chemistry

引用

页码：378 / 384

页数：7

共 3 条

[1]

Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence [J].